Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Recently, the Financial Times released an article featuring a climbing company whose goal is to offer their clients the use ...
3d
Assenagon Asset Management S.A. raised its position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) by 12.4% during the 4th quarter, HoldingsChannel reports. The fund owned 238,522 shares of ...
A breakthrough study highlights Xenon gas as a potential game-changer in treating Alzheimer’s disease, demonstrating its ...
Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a $3 billion market cap pharmaceutical company specializing in the development of therapeutic drugs, announced today the departure of its Chief Commercial ...
Study finding Xenon gas could protect against Alzheimer’s disease leads to start of clinical trial
Most treatments being pursued today to protect against Alzheimer’s disease focus on amyloid plaques and tau tangles that accumulate in the brain, but new research from Mass General Brigham and ...
Topline data from the first Phase 3 FOS study anticipated in H2 2025 representing major milestone in support of NDA filing and potential launch ...
A former British army officer is attempting the 'fastest ever' Everest mission, with help from xenon gas. Everest could be ...
Butovsky believes xenon has potential as an AD treatment. A Phase 1 clinical trial of xenon at BWH is recruiting healthy elderly volunteers to test safety and effects on immune cells. “I hope this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback